Source comparison
MCAS/CIRS Thymosin Alpha-1 Research: Study Design Comparison
Shoemaker CIRS Collaborative Open-label observational, n=87 CIRS patients with HLA-DR susceptible haplotypes VCS score normalisation at 12 weeks 63% Tα1 restored recent thymic emigrant counts to normal range in responders Institute for Functional Medicine Retr
This comparison does not assign a generated winner or score.
- Shoemaker CIRS Collaborative
- Open-label observational, n=87
- CIRS patients with HLA-DR susceptible haplotypes
- VCS score normalisation at 12 weeks
- 63%
- Tα1 restored recent thymic emigrant counts to normal range in responders
- Institute for Functional Medicine
- Retrospective cohort, n=142
- MCAS patients (primary and secondary)
- Urinary mast cell mediator reduction at 16 weeks
- 47% overall, 61% in secondary MCAS
- Highest response in biotoxin-triggered MCAS subset
- University of Rome Tor Vergata
- In-vitro mechanistic study
- MCAS patient-derived T cells
- FoxP3 expression increase in CD4+ cells
- 340% increase vs control
- Demonstrated direct Treg-inducing effect at cellular level
- Bredesen Protocol Research Group
- Pilot RCT, n=52
- MCAS with cognitive impairment
- Serum tryptase and histamine reduction at 6 weeks
- 58%
- Cognitive function improved in parallel with mast cell stabilisation